The new subsidiary follows the recent announcement of Tetra's partnership with Cannvalate Pty Ltd for the performance of clinical trials of Tetra's drug candidates in Australia.
Nulibry is approved by the U.S. Food and Drug Administration (USFDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening paediatric genetic disorder
They will commercialize molnupiravir in the international markets
Ichnos will receive an upfront payment of Euro 20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales
The company plans to raise US $ 15 million
The rolling submission to the U.S. FDA will begin in the fourth quarter of this year
The site's strategic location in the logistics hubs of the Auvergne Rhone-Alpes region is an advantage, along with the benefit of geographical proximity to Arrow's headquarters in Lyon
CuraTeQ Biologics is on track for filing a second oncology biosimilar
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
Subscribe To Our Newsletter & Stay Updated
